- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Carl Zeiss Meditec to acquire IOLTECH
Jena, Germany—Carl Zeiss Meditec has acquired a 62.69% ownership stake in the French company IOLTECH after reaching an agreement with Philippe Tourrette, IOLTECH's main shareholder, in December.
Jena, Germany-Carl Zeiss Meditec has acquired a 62.69% ownership stake in the French company IOLTECH after reaching an agreement with Philippe Tourrette, IOLTECH's main shareholder, in December.
Carl Zeiss Meditec intends a complete takeover of IOLTECH and has submitted a cash bid to all remaining shareholders. It also stated that it has received approval of the transaction by the German anti-trust authority.
IOLTECH specializes in the production and distribution of IOLs. Carl Zeiss Meditec is a supplier of medical technology. In a news release, Carl Zeiss Meditec said that "the way is now clear to merge IOLTECH's recognized high level of expertise in the surgical treatment of cataracts with Carl Zeiss Meditec's know-how in the diagnosis and postoperative treatment of eye diseases at an operative level."
